SecBot SecBot

ANRO

Alto Neuroscience, Inc.
NYSE· Pharmaceutical Preparations· Inc. DE· CIK 0001999480 Biotech & Drug Discovery
$22.92 +0.81 (+3.69%)
Oct 27 4:00 PM ET · prev $22.11
Market cap
$862.1M
Small cap
Consensus
Buy
88% Buy or better · 17 analysts
Median target
$37.00
+61% · range $26.00–60.00
1 year
+87.1%
from $12.25 · Oct 27
30 days
−14.0%
from $26.66
52-week range
$11.13–36.64
−37% from high · low Nov 6
Avg volume 20D
652.7K
Oct 14 spike 2.28M
Short interest
🔒 Subscribers only
Insider net
−$3.6M
0 buyers · 1 seller · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
12
analyzed by SecBot
SecBot read BULLISH 1 report · 90 days
Balance 0 bearish · 1 bullish oldest → newest, height = score
Avg score
Strongest BULLISH Seven institutional investors, led by BlackRock, State Street, and Geode, collectively added $67.0M in new…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $3.6M.

  • InstitutionsBULLISH

    Q2 2026: 21 added (0 new), 10 trimmed or exited.

  • AnalystsBULLISH

    15 of 17 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.798 → −$0.704 over 90 days. 3 up, 0 down in 30 days.

  • TrendDOWNTREND

    21% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.DOUBLED2,121,009$56.0M
ADAGE CAPITAL PARTNERS GP, L.L.C.DOUBLED1,600,000$42.2M
STATE STREET CORPDOUBLED685,945$18.1M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED678,199$17.9M
NORTHERN TRUST CORPADD632,701$16.7M
MILLENNIUM MANAGEMENT LLCTRIM558,320$14.7M
GOLDMAN SACHS GROUP INCDOUBLED236,830$6.2M
MARSHALL WACE, LLPADD225,503$6.0M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

17 analysts
Buy 88% rate it Buy or better
Strong Buy9Buy6Hold2Sell0Strong Sell0
12-month targets · 9 analysts

Price is below the lowest target. Median implies +61%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 19, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Aug 17, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Aug 13, 2026Wedbush
MAINTAIN
MAINTAINNeutral
Aug 13, 2026BTIG
MAINTAIN
MAINTAINBuy
May 18, 2026Baird
MAINTAIN
MAINTAINOutperform
May 14, 2026Wedbush
MAINTAIN
MAINTAINNeutral

Insider ledger

Form 4
$0
bought · 0 insiders
$3.6M
sold · 1 insider
DateInsiderTypeValue
Oct 2, 2026
Smith Nicholas Conrad
PRESIDENT AND CFO
EXERCISE$127.6K
Sep 30, 2026
Smith Nicholas Conrad
PRESIDENT AND CFO
EXERCISE$56.5K
Sep 30, 2026
Smith Nicholas Conrad
PRESIDENT AND CFO
SELL$597.3K
Sep 30, 2026
Smith Nicholas Conrad
PRESIDENT AND CFO
SELL$23.8K
Sep 29, 2026
Smith Nicholas Conrad
PRESIDENT AND CFO
EXERCISE$132.7K
Sep 29, 2026
Smith Nicholas Conrad
PRESIDENT AND CFO
EXERCISE$127.8K
Sep 29, 2026
Smith Nicholas Conrad
PRESIDENT AND CFO
SELL$2.9M
May 27, 2026
Miller Andrew Craig
Director
AWARD26,000 sh

Earnings setup

Estimates
−$0.70
EPS estimate, this quarter
+12%
estimate change, 90 days
3↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.70-$0.89–-$0.60-0.2%$0.00
Next Q-$0.73-$0.92–-$0.61-0.2%$0.00
Current FY-$2.92-$3.33–-$2.61+0.0%$0.00
Next FY-$3.19-$4.10–-$2.23+3.0%$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 Insider
Smith Nicholas Conrad acquired via exercise 55,000 shares
PRESIDENT AND CFO @ $2.32 ($127.6K)
Sep 30, 2026 Insider
Smith Nicholas Conrad acquired via exercise 24,056 shares
PRESIDENT AND CFO @ $2.35 ($56.5K)
Sep 30, 2026 Insider
Smith Nicholas Conrad sold 23,170 shares
PRESIDENT AND CFO @ $25.78 ($597.3K)
Aug 12, 2026 SEC
Seven institutional investors, led by BlackRock, State Street, and Geode, collectively added $67.0M in new ANRO…
INST-CLUSTER — Impact 6/10
Jul 15, 2026 Short interest report
Short Interest: ANRO up 29% to 3.1M shares
Settlement 2026-07-15 | Days to cover: 4.30 | ≈7.97% of shares outstanding (est.)
Jul 14, 2026 SEC
Alto Neuroscience entered into an underwriting agreement for a $100M public offering of 3,776,436 shares at $26.48 per…
8-K — Impact 6/10
Jul 14, 2026 SEC
Alto Neuroscience is conducting a $100M underwritten public offering of 3,776,436 shares at $26.48 per share…
424B5 — Impact 6/10
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
2,121,009 shares ($56.0M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Jul 15, 2026
Short interest
Short Interest: ANRO up 29% to 3.1M shares
Settlement 2026-07-15 | Days to cover: 4.30 | ≈7.97% of shares outstanding (est.)
Jun 30, 2026
Short interest
Short Interest: ANRO up 49% to 2.4M shares
Settlement 2026-06-30 | Days to cover: 2.99 | ≈6.87% of shares outstanding (est.)
Apr 17, 2026
Clinical Trial
PD, PK, and Safety of ALTO-203 in Patients With MDD
Phase 2 · COMPLETED
Apr 2, 2026
Short interest
FTD: ANRO — 71,537 shares ($1.7M) failed to deliver
Settlement: 20260402, Price: $23.41, FTD Value: $1,674,681.17, ALTO NEUROSCIENCE INC
Mar 20, 2026
Earnings date
ANRO Q4 2025 Earnings After Market Close — 2026-03-20

SecBot reports

12 filings · 4 bullish · 2 bearish · 1 mixed · 5 neutral
All ANRO filing & press-release reports (12)